In its Common Drug Review (CDR) Update – Issue 133 published on February 13, 2018, CADTH announced revisions to its biosimilar and administrative review process. This update includes the following:
- Revisions to CADTH’s biosimilar process which creates a streamlined approach for biosimilar reviews through shorter timelines, fewer submission requirements and abbreviated biosimilar summary dossier templates;
- The announcement that application fees now apply to all CDR submissions and resubmissions irrespective of the notice of compliance / notice of compliance with conditions issuance date;
- A new fee guidance for pharmaceutical review programs which includes a new, reduced fee for the new biosimilar review process and an annual fee adjustment based on the Consumer Price Index; and
- New patient input templates for biosimilars, which offers specific prompts for biosimilar review.
Other updates include the issuance of new administrative forms, such as a revised pre-submission information requirements form for advanced notice, a revised application overview template and updated contact information.
Related Publications & Articles
-
Competition Bureau’s interest in the health sector continues
Promoting competition and innovation in Canada’s health sector, including the pharmaceutical industry, is a strategic priority for the Competition Bureau. In 2021, the Bureau announced that it joined ...Read More -
Federal Court sets aside decision by the Minister of Health to issue RUZURGI NOC for the second time
On March 10, 2022, for the second time, the Federal Court set aside a decision by the Minister of Health (Minister) to issue Médunik Canada (Médunik) a Notice of Compliance (NOC) for its amifampridine...Read More -
New guidance documents and regulatory amendments regarding therapeutic product shortages
As we have previously reported, in response to the COVID-19 pandemic, the Minister of Health had made interim orders pursuant to the Food and Drugs Act to address the significant risk to health posed ...Read More